Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 28.6%High 5 · 71.4%

Brexpiprazole vs antidepressive agents

Response to treatment at 8 weeks · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole leads to higher response to treatment at 8 weeks compared with antidepressive agents (high certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 1.47 [1.23, 1.75]
8 studies · 3409 participants
High

Brexpiprazole vs antidepressive agents

Acceptability ‐ total dropouts · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole leads to higher number of dropouts due to any cause at 8 weeks compared with antidepressive agents (high certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 1.37 [1.02, 1.83]
7 studies · 2523 participants
High

Brexpiprazole vs antidepressive agents

Adverse effects (dropouts) · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 2.88 [1.37, 6.05]
6 studies · 2472 participants
High

Brexpiprazole vs antidepressive agents

Remission · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole leads to higher remission rates at 8 weeks compared with antidepressive agents (high certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 1.46 [1.19, 1.79]
7 studies · 3358 participants
High

Brexpiprazole vs antidepressive agents

Change in depressive symptoms · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole showed no clear difference in change in depressive symptoms at 8 weeks compared with antidepressive agents (high certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
MD 1.39
8 studies · 3263 participants
High

Brexpiprazole vs antidepressive agents

Adverse effects: 2. Extrapyramidal ‐ akathisia · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole probably leads to higher adverse effects: akathisia (followed up until the end of the longest compared with antidepressive agents (moderate certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 2.95 [2.06, 4.21]
7 studies · 3358 participants
Moderate

Brexpiprazole vs antidepressive agents

Weight gain · participants of any age with a primary diagnosis of major depressive disorder

Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).

1 finding from 1 review

Brexpiprazole versus placebo or other antidepressive agents for treating depression 2023 · Cochrane Headline outcomes only
OR 3.14 [2.19, 4.49]
9 studies · 3424 participants
Moderate